We find in this study that PI3K inhibition by an anti-PI3Kα/β/δ inhibitor, BAY1082439, not only inhibits PTEN null prostate cancer cell growth, but also promotes anti-tumor immunity in the endogenous Pten-null prostate cancer model. This evidence concerns the gene PTEN and prostate carcinoma.